Diabetes, Heart and Cardiovascular Diseases News Chronicle.  Diabetes, Cardiovascular and Heart Diseases
 Article 262
    Published on October 25, 2017


Better HbA1c A1C or glycemic control without hypoglycemic events with Dapagliflozin (Forxiga) drug in type 1 diabetic patients

Even though glycemic levels are under control in type 1 diabetes (T1D) patients, they may experience "glycemic excursions" (blood sugar or glucose or glycemic levels changing from hyperglycemic or high levels to hypoglycemic or low levels) with insulin. A study funded by dapagliflozin drug (a SGLT2 inhibitor) development partners, Bristol-Myers Squibb and AstraZeneca, shows marked reduction in blood sugar levels in most of the type 1 diabetes (T1D) patients with dapagliflozin drug. Currently, dapagliflozin drug was being used to treat patients with type 2 diabetes (T2D).


Researchers have conducted a 24 week study, named as Dapagliflozin in Patients with Inadequately Controlled Type 1 diabetes (T1D) study (DEPICT-1), the first Phase 3 trial, in 17 countries, including the United States to find out dapagliflozin drug efficacy and safety as an adjunct treatment for insulin, for the treatment of type 1 diabetes (T1D) patients with inadequately controlled blood glucose levels. The total number of the participants were 833, aged between 18 and 75 years.

The study results show approximately 50 percent of the type 1 diabetes (T1D) patients have successfully reduced their A1C levels by more than 0.5 percent without low blood sugar levels (hypoglycemia) events. The authors say that the dapagliflozin drug is eligible for license by the United States FDA as an antidiabetic agent for type 1 diabetes (T1D) patients as the drug reduces HbA1c levels by about 0.5 percent. But they say the drug needs further studies to confirm the current study findings.



Dapagliflozin Forxiga SGLT2 provides HbA1c A1C glycemic blood sugar or glucose control of type 1 diabetic without hypoglycemic.

Manufacturers likely to apply for United States FDA licensing after getting the results of DEPICT-1 at 56-week study and DEPICT-2, a parallel dapagliflozin medication study. Senior author of the study was Professor Paresh Dandona, MD, PhD, chief of endocrinology, diabetes and metabolism, Jacobs School of Medicine and Biomedical Sciences, the University at Buffalo.




Facebook     GooglePlus     Twitter
If you like this article, please share it with a friend! Article address is (copy and paste the code below) :

Articles similar to this topic


1. Trials Of GLP-1 (exenatide extended-release) And Farxiga (dapagliflozin)
2. Chronic Kidney Disease, Heart Disease & Diabetes Prevention Drugs From Forxiga Drug Maker AstraZeneca
3. Ghrelin Hormone Could Expand Diabetes Treatments And Hypoglycemia
4. Eating cocoa, chocolate reduces blood sugar or glucose levels, obesity and increases insulin secretion
5. Coronary artery bypass surgery (CABG) is effective in treating artherosclerotic coronary arteries among type 1 diabetes patients
6. Higher risk of the development type 1 diabetes (T1D) in early term or early birth babies
7. Trials With Forxiga (Dapagliflozin), Victoza (Liraglutide) And Insulin Approach (Triple Therapy)
8. Toujeo Lowers Hypoglycemia Events Among Insulin Dependent Type 2 Diabetes Patients
9. MonoPepT1De trial shows slowdown in the development of type 1 diabetes with a retrained immune system
10. A cure for Type 1 Diabetes (T1D) With Gene Transfer Technique

 

 

The risk for type 2 diabetes, type 1.5 diabetes or latent autoimmune diabetes in adults (LADA) with high salt or sodium consumption

A study done by researchers at the Institute of Environmental Medicine (IMM), Karolinska Institutet, Sweden shows twice likely risk of the development of diabetes (apart from the risk of high blood pressure BP or hypertension) among those people who consume more salt (as 40 percent of salt is sodium). Researchers say salt directly affects insulin resistance.


The study results show 43 percent increased risk for the development of type 2 diabetes (T2D) with 2.5 grams of extra salt consumption (equal to 1 gram of sodium) per day. The study also shows 72 percent increased risk for the development of type 2 diabetes (T2D) in individuals who consume more than 7.3 grams of salt per day when compared with individuals who consume less than 6 grams of salt per day.

Individuals with human leukocyte antigen (HLA) protein and consuming high salt (more than 3.15 grams of salt per day) are at four times higher risk of the development of type 1.5 diabetes or latent autoimmune diabetes in adults (LADA) compared with individuals consuming low (less than 2.4 grams of salt per day).


Type 2 diabetes and latent autoimmune diabetes (1.5) in adults (LADA) with high salt sodium diet.

Lead authors of the study were Bahareh Rasouli, the Institute of Environmental Medicine (IMM). The study findings were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) 2017, Lisbon, Portugal and published on September 14, 2017, in the Diabetologia. Title of the article was "Sodium (salt) intake is associated with a risk of developing type 2 diabetes."




Facebook     GooglePlus     Twitter
Post a message on social media and mail to your friend. Article address is (copy and paste the code below) :

Articles similar to this topic


1. Too much salt consumption may double heart failure, stroke and coronary heart disease (CHD)
2. Salty Skin In People With Kidney Disease Could Be A Sign Of a Heart Problem
3. Insufficient sleep hours increases the risk for type 2 diabetes, insulin resistance and body fat in children
4. Neovacs Vaccine To Treat Type 1 Diabetes (T1D)
5. ViaCyte conducts embryonic stem cell implant trials in high-risk type 1 diabetes patients
6. High Salt Diet Putting Teens At Risk Of Heart Disease Later In Life
7. Increase In Diabetes And Insulin Resistance With Climate Change
8. About type 1 disease (T1D) And type 2 Diabetes (T2D)
9. Enhanced risk for celiac disease in type 1 diabetes in children
10. Limit Consumption Of Salt, Sugar And Saturated Fat To Keep Good Heart Health

 

Type 1.5 diabetes : Type 1.5 diabetes or latent autoimmune diabetes in adults (LADA) is a type 1 diabetes (T1D) which appears during adulthood. The onset of LADA in adulthood is slower when compared to the onset of type 1 diabetes (T1D) in childhood. This occurs due to the destruction or damage to the insulin-producing beta cells in the pancreas.

 

 

Site maps

Site map 1   Site map 2   Site map 3   Site map 4


The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.